Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Retained Earnings (2022 - 2025)

Zentalis Pharmaceuticals has reported Retained Earnings over the past 4 years, most recently at -$1.2 billion for Q4 2025.

  • Quarterly results put Retained Earnings at -$1.2 billion for Q4 2025, down 213622.4% from a year ago — trailing twelve months through Dec 2025 was -$1.2 billion (down 213622.4% YoY), and the annual figure for FY2025 was -$1.2 billion, down 213622.4%.
  • Retained Earnings for Q4 2025 was -$1.2 billion at Zentalis Pharmaceuticals, down from $186000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for ZNTL hit a ceiling of $2.2 million in Q4 2023 and a floor of -$1.2 billion in Q4 2025.
  • Median Retained Earnings over the past 4 years was -$1.2 million (2022), compared with a mean of -$361.7 million.
  • Biggest five-year swings in Retained Earnings: skyrocketed 262.16% in 2023 and later crashed 806920.0% in 2025.
  • Zentalis Pharmaceuticals' Retained Earnings stood at -$1.4 million in 2022, then skyrocketed by 262.16% to $2.2 million in 2023, then plummeted by 74.57% to $558000.0 in 2024, then tumbled by 213622.4% to -$1.2 billion in 2025.
  • The last three reported values for Retained Earnings were -$1.2 billion (Q4 2025), $186000.0 (Q3 2025), and -$1.1 billion (Q2 2025) per Business Quant data.